{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T15:06:17Z","timestamp":1790867177084,"version":"4.1.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"vor","delay-in-days":40,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Tropical Disease Research, World Health Organization","award":["2021\/1188581-0"],"award-info":[{"award-number":["2021\/1188581-0"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-026-13156-2","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T01:16:20Z","timestamp":1774574180000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cohort evaluation of an all-oral shorter regimen for drug-resistant tuberculosis in Ecuador"],"prefix":"10.1186","volume":"26","author":[{"given":"Adriana","family":"Chac\u00f3n","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yamile Celis","family":"Bustos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dany","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Chong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Freile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Ayala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amadou","family":"Seck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatimata Bintou","family":"Sall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne Simone","family":"Merle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2001-0057","authenticated-orcid":false,"given":"Freddy","family":"Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,27]]},"reference":[{"key":"13156_CR1","unstructured":"Organizaci\u00f3n Panamericana de la Salud. Tuberculosis - OPS\/OMS | Organizaci\u00f3n Panamericana de la Salud [Internet]. [cited 2024 May 22]. Available from: https:\/\/www.paho.org\/es\/temas\/tuberculosis."},{"key":"13156_CR2","unstructured":"World Health Organization. Global tuberculosis report 2024 [Internet]. Geneva. 2024 [cited 2025 Nov 30]. Available from: https:\/\/iris.who.int\/server\/api\/core\/bitstreams\/7292c91e-ffb0-4cef-ac39-0200f06961ea\/content."},{"key":"13156_CR3","unstructured":"World Health Organization. Global tuberculosis report 2023 [Internet]. Geneva; 2023 [cited 2023 Dec 22]. Available from: https:\/\/iris.who.int\/."},{"key":"13156_CR4","unstructured":"World Health Organization. TB profile [Internet]. 2023 [cited 2025 Jan 28]. Available from: https:\/\/worldhealthorg.shinyapps.io\/tb_profiles\/?_inputs_%26tab=%22tables%22%26lan=%22ES%22%26iso2=%22EC%22%26entity_type=%22country%22."},{"key":"13156_CR5","unstructured":"Ministerio de Salud P\u00fablica de Ecuador. Bolet\u00edn estrat\u00e9gico 2019\u20132022. Estrategia nacional de tuberculosis. [Internet]. Quito, Ecuador. 2023 [cited 2024 Jul 10]. Available from: Bolet\u00edn Estrat\u00e9gico Estrategia Nacional de TB 2019\u20132022."},{"key":"13156_CR6","unstructured":"World Health Organization. WHO consolidated guidelines on tuberculosis. Module 3: Diagnosis- Rapid diagnostics for tuberculosis detection. Third edition. [Internet]. Geneva; 2024 [cited 2025 Dec 3]. Available from: https:\/\/www.who.int\/publications\/i\/item\/9789240089488."},{"key":"13156_CR7","unstructured":"World Health Organization. Module 4: Treatment WHO operational handbook on tuberculosis Drug-resistant tuberculosis treatment 2022 update [Internet]. 2022 [cited 2024 Jan 14]. Available from: https:\/\/www.who.int\/publications\/i\/item\/9789240065116."},{"key":"13156_CR8","unstructured":"World health organization. ShORRT (Short, all-oral regimens for rifampicin-resistant tuberculosis) research package protocol [Internet]. 2020 [cited 2024 Jan 28]. Available from: https:\/\/tdr.who.int\/docs\/librariesprovider10\/shorrt-initiative\/shorrt-generic-protocol-june2020_en.pdf?sfvrsn=df85f6c1_3."},{"key":"13156_CR9","unstructured":"World Health Organization. The ShORRT initiative on tuberculosis research in the Region of the Americas [Internet]. 2022 [cited 2023 Dec 23]. Available from: https:\/\/tdr.who.int\/newsroom\/news\/item\/25-05-2022-the-shorrt-initiative-on-tuberculosis-research-in-the-region-of-the-americas."},{"key":"13156_CR10","unstructured":"National Institutes of Allergy and Infectious Diseases, National Institutes of Health. Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events. 2017."},{"key":"13156_CR11","unstructured":"Cancer Institute N. Common terminology criteria for adverse events (CTCAE) v5.0 [Internet]. 2017. Available from: https:\/\/www.meddra.org\/."},{"key":"13156_CR12","unstructured":"REDCap [Internet]. [cited 2024 Mar 11]. Available from: https:\/\/redcap.paho.org\/redcap_v13.1.30\/DataEntry\/index.php?pid=598%26id=18%26event_id=655%26page=regional_cro_assessment_tool_main."},{"key":"13156_CR13","doi-asserted-by":"publisher","unstructured":"Zou GA. Modified poisson. Regression approach to prospective studies with binary data. Am J Epidemiol [Internet]. 2004 Apr 1 [cited 2025 Dec 22];159(7):702\u20136. Available from: https:\/\/doi.org\/10.1093\/aje\/kwh090.","DOI":"10.1093\/aje\/kwh090"},{"key":"13156_CR14","doi-asserted-by":"publisher","unstructured":"Zou GY, Donner A. Extension of the modified poisson regression model to prospective studies with correlated binary data. Stat Methods Med Res [Internet]. 2013 Dec [cited 2025 Dec 22];22(6):661\u201370. Available from: https:\/\/doi.org\/10.1177\/0962280211427759?download=true.","DOI":"10.1177\/0962280211427759?download=true"},{"key":"13156_CR15","unstructured":"Organizaci\u00f3n Panamericana de la Salud. Tuberculosis en las Am\u00e9ricas. Informe regional 2021 [Internet]. Washington. 2022. Available from: https:\/\/iris.paho.org\/bitstream\/handle\/10665.2\/57084\/9789275326497_spa.pdf?sequence=11%26isAllowed=y."},{"key":"13156_CR16","doi-asserted-by":"crossref","unstructured":"Wahid A, Ghafoor A, Khan AW, Al-Worafi YM, Latif A, Shahwani NA, et al. Comparative effectiveness of individualized longer and standardized shorter regimens in the treatment of multidrug resistant tuberculosis in a high burden country. Front Pharmacol [Internet]. 2022 Sep 6 [cited 2024 Aug 30];13. Available from: https:\/\/www.pmc\/articles\/PMC9503836\/.","DOI":"10.3389\/fphar.2022.973713"},{"key":"13156_CR17","doi-asserted-by":"crossref","unstructured":"Trubnikov A, Hovhannesyan A, Akopyan K, Ciobanu A, Sadirova D, Kalandarova L, et al. Effectiveness and safety of a shorter treatment regimen in a setting with a high burden of multidrug-resistant tuberculosis. Int J Environ Res Public Health [Internet]. 2021 Apr 2 [cited 2024 Aug 28];18(8):4121. Available from: http:\/\/www.pmc\/articles\/PMC8069801\/.","DOI":"10.3390\/ijerph18084121"},{"issue":"91","key":"13156_CR18","doi-asserted-by":"publisher","first-page":"S66","DOI":"10.3855\/jidc.13757","volume":"15","author":"E Zhdanova","year":"2021","unstructured":"Zhdanova E, Goncharova O, Davtyan H, Alaverdyan S, Sargsyan A, Harries AD, et al. 9\u201312 months short treatment for patients with MDR-TB increases treatment success in Kyrgyzstan. J Infect Dev Ctries. 2021;15(91):S66\u201374.","journal-title":"J Infect Dev Ctries"},{"key":"13156_CR19","doi-asserted-by":"publisher","unstructured":"Sinha P, Jacobson KR, Robert HorsburghJr C, Acu\u00f1a-Villaordu\u00f1a C. At long last: short, all-oral regimens for multidrug-resistant tuberculosis in the United States. 2023 [cited 2024 Aug 30]; Available from: https:\/\/doi.org\/10.1093\/ofid\/ofad177.","DOI":"10.1093\/ofid\/ofad177"},{"key":"13156_CR20","doi-asserted-by":"crossref","unstructured":"Gu P, Lu P, Ding H, Liu Q, Ding X, Chen Y, et al. Effectiveness, cost, and safety of four regimens recommended by WHO for RR\/MDR-TB treatment: a cohort study in Eastern China. Ann Med [Internet]. 2024 [cited 2024 Aug 30];56(1):2344821. Available from: http:\/\/www.pmc\/articles\/PMC11067554\/.","DOI":"10.1080\/07853890.2024.2344821"},{"key":"13156_CR21","doi-asserted-by":"crossref","unstructured":"Huerga H, Khan U, Bastard M, Mitnick CD, Lachenal N, Khan PY, et al. Safety and effectiveness outcomes from a 14-country cohort of patients with multi-drug resistant tuberculosis treated concomitantly with bedaquiline, delamanid, and other second-line drugs. Clin Infect Dis [Internet]. 2022 Oct 15 [cited 2024 Aug 6];75(8):1307\u201314. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/35243494\/.","DOI":"10.1093\/cid\/ciac176"},{"key":"13156_CR22","doi-asserted-by":"crossref","unstructured":"Rodr\u00edguez M, Celis Bustos Y, Encarnaci\u00f3n M, Mu\u00f1oz E, De los Santos S, Sanch\u00e9z I, et al. Evaluation of a modified short all oral treatment regimen for rifampicin-multidrug resistant tuberculosis in Dominican Republic. 2024 Apr 29 [cited 2024 Sep 2]; Available from: https:\/\/www.researchsquare.com.","DOI":"10.1186\/s12879-024-10417-w"},{"key":"13156_CR23","doi-asserted-by":"crossref","unstructured":"Reuter A, Tisile P, Von Delft D, Cox H, Cox V, Ditiu L, et al. The devil we know: is the use of injectable agents for the treatment of MDR-TB justified? Int J Tuberculosis Lung Disease. 2017;21(11).","DOI":"10.5588\/ijtld.17.0468"},{"key":"13156_CR24","doi-asserted-by":"crossref","unstructured":"Borisov S, Danila E, Maryandyshev A, Dalcolmo M, Miliauskas S, Kuksa L, et al. Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report. Eur Respir J [Internet]. 2019 Dec 1 [cited 2024 Mar 1];54(6). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/31601711\/.","DOI":"10.1183\/13993003.01522-2019"},{"key":"13156_CR25","doi-asserted-by":"crossref","unstructured":"Ghafari N, Court R, Chirehwa MT, Wiesner L, Petersen L, Maartens G, et al. Pharmacokinetics and other risk factors for kanamycin-induced hearing loss in patients with multi-drug resistant tuberculosis. Int J Audiol [Internet]. 2020 Mar 3 [cited 2024 Aug 30];59(3):219\u201323. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/31739701\/.","DOI":"10.1080\/14992027.2019.1690170"},{"key":"13156_CR26","doi-asserted-by":"crossref","unstructured":"Poka-Mayap V, Balkissou Adamou D, Pefura-Yone EW, Kuaban C. Kanamycin-induced ototoxicity during treatment of multidrug-resistant tuberculosis. Rev Mal Respir [Internet]. 2020 May 1 [cited 2024 Aug 30];37(5):369\u201375. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/32278508\/.","DOI":"10.1016\/j.rmr.2019.12.005"},{"key":"13156_CR27","doi-asserted-by":"crossref","unstructured":"Hong H, Dowdy DW, Dooley KE, Francis HW, Budhathoki C, Han HR, et al. Risk of hearing loss among multidrug-resistant tuberculosis patients according to cumulative aminoglycoside dose. Int J Tuberc Lung Dis [Internet]. 2020 Jan 1 [cited 2026 Mar 23];24(1):65\u201372. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/32005308\/.","DOI":"10.5588\/ijtld.19.0062"},{"key":"13156_CR28","doi-asserted-by":"crossref","unstructured":"Souleymane MB, Piubello A, Lawan IM, Hassane-Harouna S, Assao-Neino MM, Soumana A, et al. High rifampicin-resistant TB cure rates and prevention of severe ototoxicity after replacing the injectable by linezolid in early stage of hearing loss. Eur Respir J [Internet]. 2021 Jan 1 [cited 2025 Dec 4];57(1). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/32703777\/.","DOI":"10.1183\/13993003.02250-2020"},{"key":"13156_CR29","unstructured":"Sguassero Y, Roberts KN, Harvey GB, Comand\u00e9 D, Ciapponi A, Cuesta CB, et al. Course of serological tests in treated subjects with chronic trypanosoma cruzi infection: a systematic review and meta-analysis of individual participant data. Int J Infect Dis [Internet]. 2018 Aug 1 [cited 2023 Dec 12];73:93. Available from: https:\/\/www.pmc\/articles\/PMC6069672\/."},{"key":"13156_CR30","doi-asserted-by":"crossref","unstructured":"Motta I, Boeree M, Chesov D, Dheda K, G\u00fcnther G, Horsburgh CR, et al. Recent advances in the treatment of tuberculosis. Clin Microbiol Infect [Internet]. 2023 Sep 1 [cited 2024 Aug 30];30(9):1107\u201314. Available from: http:\/\/www.clinicalmicrobiologyandinfection.com\/article\/S1198743X23003397\/fulltext.","DOI":"10.1016\/j.cmi.2023.07.013"},{"key":"13156_CR31","doi-asserted-by":"crossref","unstructured":"Lan Z, Ahmad N, Baghaei P, Barkane L, Benedetti A, Brode SK, et al. Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet Respir Med [Internet]. 2020 Apr 1 [cited 2024 Aug 6];8(4):383\u201394. Available from: http:\/\/www.thelancet.com\/article\/S2213260020300473\/fulltext.","DOI":"10.1016\/S2213-2600(20)30047-3"},{"issue":"4","key":"13156_CR32","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S2213-2600(20)30047-3","volume":"8","author":"Z Lan","year":"2020","unstructured":"Lan Z, Ahmad N, Baghaei P, Barkane L, Benedetti A, Brode SK, et al. Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet Respir Med. 2020;8(4):383\u201394.","journal-title":"Lancet Respir Med"},{"key":"13156_CR33","unstructured":"Disability. comorbidities and risk determinants at end of TB treatment in Kenya, Uganda, Zambia and Zimbabwe | The Union [Internet]. [cited 2024 Aug 30]. Available from: https:\/\/theunion.org\/news\/disability-comorbidities-and-risk-determinants-at-end-of-tb-treatment-in-kenya-uganda-zambia-and-zimbabwe."},{"key":"13156_CR34","doi-asserted-by":"publisher","first-page":"1253615","DOI":"10.3389\/fpubh.2023.1253615","volume":"11","author":"A Nowi\u0144ski","year":"2023","unstructured":"Nowi\u0144ski A, Weso\u0142owski S, Korzeniewska-Kose\u0142a M. The impact of comorbidities on tuberculosis treatment outcomes in Poland: a national cohort study. Front Public Health. 2023;11:1253615.","journal-title":"Front Public Health"},{"key":"13156_CR35","unstructured":"Co-morbidities [Internet]. [cited 2024 Aug 30]. Available from: https:\/\/www.who.int\/southeastasia\/activities\/co-morbidities-tb."},{"key":"13156_CR36","doi-asserted-by":"crossref","unstructured":"Hogan AB, Jewell BL, Sherrard-Smith E, Vesga JF, Watson OJ, Whittaker C, et al. Potential impact of the COVID-19 pandemic on HIV, tuberculosis, and malaria in low-income and middle-income countries: a modelling study. Lancet Glob Health [Internet]. 2020 Sep 1 [cited 2025 Nov 30];8(9):e1132\u201341. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/32673577\/.","DOI":"10.1016\/S2214-109X(20)30288-6"},{"key":"13156_CR37","doi-asserted-by":"crossref","unstructured":"Rodrigues I, Aguiar A, Migliori GB, Duarte R. Impact of the COVID-19 pandemic on tuberculosis services. Pulmonology [Internet]. 2022 May 1 [cited 2025 Dec 3];28(3):210\u20139. Available from: https:\/\/www.journalpulmonology.org\/en-impact-covid-19-pandemic-on-tuberculosis-articulo-S2531043722000277.","DOI":"10.1016\/j.pulmoe.2022.01.015"},{"key":"13156_CR38","unstructured":"Pan American Health Organization. Health in the Americas 2022: Overview of the Region of the Americas in the Context of the COVID-19 Pandemic [Internet]. Washington, D.C. 2022 [cited 2025 Dec 3]. Available from: https:\/\/iris.paho.org\/server\/api\/core\/bitstreams\/a7a1f8b3-7ab0-428c-b000-394eb116833d\/content."}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-026-13156-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13156-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13156-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T23:25:51Z","timestamp":1778023551000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-026-13156-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,27]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["13156"],"URL":"https:\/\/doi.org\/10.1186\/s12879-026-13156-2","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,27]]},"assertion":[{"value":"13 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study obtained ethical approval from the WHO Research Ethics Review Board (Generic Protocol ID: ERC0003305, 08\/06\/2020) and the Ethics Committee of the Ministry of Health of Ecuador. Written and signed informed consent was obtained from each patient before any procedures were performed. For participants under the age of 16, consent to participate was obtained from their parents or legal guardians. All methods adhered to relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"All authors and respondents involved in this research have consented to the publication of all paper details, data, tables, and images. These materials will be freely accessible on the internet.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"YCB, AS, FBS, CSM, and FP are staff members of the World Health Organization (WHO). The views expressed in this publication are solely those of the authors and do not necessarily represent the decisions, policies, or views of the WHO.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}},{"value":"The findings and conclusions presented in this article are the intellectual responsibility of the authors and do not necessarily represent the official position of the World Health Organization Special Programme for Research and Training in Tropical Diseases, the Pan American Health Organization, or the Ministry of Public Health of Ecuador.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Legal notice"}},{"value":"The authors declare no competing interests.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"902"}}